FTIR

Agilent Presents Solutions Innovation Research Awards to Cornell and Indiana University Researchers

Retrieved on: 
星期四, 五月 16, 2024
Other Energy, Hardware, Sustainability, Alternative Energy, Batteries, Energy, Technology, University, Environment, Semiconductor, Education, Green Technology, Nanotechnology, Indiana University, External, Electrocatalyst, FTIR, SIRA, Research, Professor, Associate, Cornell University

Agilent Technologies Inc. (NYSE: A) today announced two Solutions Innovation Research Awards (SIRA) presented to Professors Richard Robinson of Cornell University and Xingchen Ye of Indiana University .

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced two Solutions Innovation Research Awards (SIRA) presented to Professors Richard Robinson of Cornell University and Xingchen Ye of Indiana University .
  • These separate awards recognize their outstanding contributions to advanced materials research.
  • The Solutions Innovation Research Award (SIRA) program, under the guidance of Dr. Chong Wing Yung, Associate Director of University Relations and External Research at Agilent, is designed to stimulate the most innovative and impactful use of Agilent products to help solve pressing scientific problems in academia.
  • For more information about the Agilent Solutions Innovation Research Award (SIRA) visit www.agilent.com/univ_relation/SIRA .

Global IR Spectroscopy Industry Research 2024-2029: Continuous Technological Advancements, Increase in R&D Investments, Growth in Healthcare Institutions and Clinical Research Centers - ResearchAndMarkets.com

Retrieved on: 
星期二, 五月 14, 2024
Technology, Agritech, Fertility, Countertop, Health care, Biomedical Research, Sartorius AG, Biology, Environmental monitoring, USD, Continuity, Availability, Agriculture, Soil, FTIR, NIRS, Science, Investment, Growth, Ecosystem, Food, Gas, Health, ABB, Potassium, Research, Technical, Phosphorus, PerkinElmer, Polymer, Thermo Fisher Scientific, Agilent Technologies, Bruker, Nitrogen, Shimadzu

Supply chain analysis has been included in the report, along with the key players and their competitive analysis in the IR spectroscopy ecosystem.

Key Points: 
  • Supply chain analysis has been included in the report, along with the key players and their competitive analysis in the IR spectroscopy ecosystem.
  • Continuous technological advancements in IR spectroscopy is driving the growth of the IR spectroscopy market.
  • Whereas availability of used IR spectroscopy devices is restraining the growth of the IR spectroscopy market.
  • Key Benefits to Buy the Report:
    Analysis of key drivers (Growth in the number of healthcare institutions and clinical research centers, Increase in R&D investments in healthcare and pharmaceuticals industry, Continuous technological advancements in IR spectroscopy).

RedShiftBio Launches Aurora TX: Revolutionizing RNA and Protein Analysis with Ultra-Sensitive Microfluidic Modulation Spectroscopy and Thermal Ramping Capability

Retrieved on: 
星期一, 五月 13, 2024
LNP, MMS, System, Protein, FTIR, Microfluidic modulation spectroscopy, PEGS, Dicarboxylic acid, Drug discovery, RNA, Peptide, Vaccine

BOXBOROUGH, Mass., May 13, 2024 /PRNewswire/ -- RedShiftBio, a leader in innovative biophysical characterization and bioprocess analytical solutions, proudly announces the launch of Aurora TX at The Protein & Antibody Engineering Summit (PEGS), kicking off on May 13, 2024, in Boston, MA. Aurora TX is the company's latest, most advanced instrument featuring ground-breaking MMS technology, and sets a new standard in biomolecular analysis by providing ultra-sensitive, ultra-precise measurements of biomolecule structure and stability, now enhanced with the addition of thermal ramping capability.

Key Points: 
  • Aurora TX characterizes structure and stability of RNA, proteins, and more, along with new thermal ramping capability.
  • One of the most noteworthy advancements of Aurora TX is its growing application in RNA analysis.
  • Researchers can use Aurora TX to detect structural changes to RNA due to sequence modifications, formulation changes, and thermal stress.
  • Key features of Aurora TX include:
    For more information about Aurora TX and RedShiftBio's innovative solutions, visit www.redshiftbio.com/products/aurora-tx

908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering

Retrieved on: 
星期二, 四月 30, 2024
Health, Medical Devices, Technology, Health Technology, Pharmaceutical, Hardware, Biotechnology, Diamond, MASS, Aerosol, Spectroscopy, Webcast, QC, Environment, Acquisition, Process analytical technology, PAT, Fourier transform, FTIR, Management

In addition, RedWave bolsters 908 Devices’ desktop portfolio with a line of accessories for pharma Process Analytical Technology (PAT) and industrial QC applications.

Key Points: 
  • In addition, RedWave bolsters 908 Devices’ desktop portfolio with a line of accessories for pharma Process Analytical Technology (PAT) and industrial QC applications.
  • “We’re thrilled to welcome the RedWave team to 908 Devices.
  • RedWave is a strong fit and enables us to accelerate our strategic objectives.”
    “RedWave Technology and 908 Devices share an extraordinary passion for innovation and customer care,” said Jon Frattaroli, CEO of RedWave Technology, now VP, Strategy at 908 Devices.
  • RedWave is expected to contribute $11 million to 908 Devices’ 2024 reported revenue, representing eight months of ownership.

Dxcover invited to present its CREATE-2 clinical trial for the early detection of colorectal cancer and advanced adenoma at the American Association for Cancer Research Annual Meeting 2024 in San Diego CA April 10

Retrieved on: 
星期四, 四月 4, 2024
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Colonoscopy, Algorithm, Survival, Colorectal cancer, Patient, Cancer, Quality of life, FTIR, Machine learning, Blood, Fourier, Medical imaging

The CREATE-2 trial evaluates diagnostic accuracy for colorectal cancer and high-risk adenoma in patients undergoing a colonoscopy.

Key Points: 
  • The CREATE-2 trial evaluates diagnostic accuracy for colorectal cancer and high-risk adenoma in patients undergoing a colonoscopy.
  • The prospective observational study has two recruitment pathways, one in the US (targeting 1000 patients) and one in the UK (targeting 700 patients).
  • CREATE-2 intends to validate the previous feasibility study results from CREATE-1 which showed Dxcover’s ability to achieve accurate detection of pre-cancerous lesions and stage 1 colorectal cancer.
  • Dxcover’s Multi-Omic Spectral Analysis (MOSA-Dx™) enables analysis the full complement of signals within the blood to provide early detection of cancer.

Specac, Ltd Acquires Harrick Scientific

Retrieved on: 
星期二, 四月 2, 2024
Growth, Harrick, General partnership, Acquisition, FTIR, Life, OEM, Interim

ORPINGTON, England, April 2, 2024 /PRNewswire/ -- Specac, Ltd ("Specac"), a portfolio company of Ampersand Capital Partners and leader in the design and manufacture of spectroscopy accessories and sample prep solutions, announced today the acquisition of Harrick Scientific, Inc ("Harrick"), a well-known manufacturer of high-quality spectroscopy equipment and optical components. The newly combined companies will drive new synergies and growth between two recognized leaders in the spectroscopy OEM accessories market.

Key Points: 
  • ORPINGTON, England, April 2, 2024 /PRNewswire/ -- Specac, Ltd ("Specac"), a portfolio company of Ampersand Capital Partners and leader in the design and manufacture of spectroscopy accessories and sample prep solutions, announced today the acquisition of Harrick Scientific, Inc ("Harrick"), a well-known manufacturer of high-quality spectroscopy equipment and optical components.
  • The newly combined companies will drive new synergies and growth between two recognized leaders in the spectroscopy OEM accessories market.
  • Laurie Miller, President of Harrick, comments, "As a family-founded business, we are incredibly proud of the successful business we've grown thanks to the dedication of our talented Harrick team.
  • Specac and Harrick have complementary and high-quality product offerings, long-standing client relationships, and impressive track records of continual innovation.

Ampersand Capital Partners Acquires Specac, Ltd.

Retrieved on: 
星期三, 三月 13, 2024
FTIR, Acquisition, Spectroscopy, OEM, Investment

ORPINGTON, England, March 13, 2024 /PRNewswire/ -- Ampersand Capital Partners ("Ampersand"), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announced today the acquisition of Specac Limited ("Specac"), an industry leader in the design and manufacture of spectroscopy accessories and sample prep solutions.

Key Points: 
  • ORPINGTON, England, March 13, 2024 /PRNewswire/ -- Ampersand Capital Partners ("Ampersand"), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announced today the acquisition of Specac Limited ("Specac"), an industry leader in the design and manufacture of spectroscopy accessories and sample prep solutions.
  • "On behalf of the entire Specac organization, we are excited to partner with the Ampersand team and join its diverse portfolio of companies.
  • Specac employs around 80 people with offices in the US and UK, supported by a global network of distributors and dealers.
  • David Patteson, Partner at Ampersand, adds, "We are thrilled to partner with the entire Specac team.

Symphony hails US Environmental Protection Agency report on pro-oxidants

Retrieved on: 
星期一, 三月 11, 2024
Depolymerization, TGA, FTIR, Spectroscopy, GC, Microplastics, Water, Fourier, Plastic, Environment, Ageing, PP

LONDON, March 11, 2024 /PRNewswire/ -- Symphony Environmental Technologies Plc. have commented on this important statement from the US Environmental Protection Agency (EPA). 

Key Points: 
  • Blending plastics with pro-oxidants could be a promising solution, as they accelerate photooxidation to obtain degradable materials whose final ecological and physical footprint are much smaller."
  • "In this study, two pro-oxidants, iron stearate (FeSt3) and cobalt stearate (CoSt2), were melt-blended with polypropylene (PP) at concentrations of 1 and 2 wt%.
  • After 500 h of aging plastics plates showed significant reduction in melting and re-crystallization points - indicating polymer-chain breaking, rapid depolymerization."
  • The study offers a successful approach where benign filler could significantly reduce the persistence of plastic pollution without creating undesired by-products."

Dxcover Announces Three New Clinical Trials for Brain, Colorectal and Lung Cancer Detection

Retrieved on: 
星期二, 一月 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Brain, FTIR, CREATE, Patient, Fourier, European Innovation Council, IVD, Cancer, Algorithm, Colonoscopy, Brain tumor, Disease, NHS, Machine learning, NHS Lothian, Colorectal cancer, EMBRACE, Medical imaging

Dxcover Limited , a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer.

Key Points: 
  • Dxcover Limited , a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer.
  • The company has launched its EMBRACE study, a 2,200-patient trial focused on the early detection of brain cancer.
  • Dxcover® Brain Cancer is a qualitative in vitro diagnostic (IVD) test analyzing blood serum by infrared spectroscopy to detect the signals indicative of brain cancer.
  • The Dxcover Brain Cancer test has been developed over four years with clinical support from NHS Lothian.

Kyocera develops silicon nitride light source for high-performance FTIR spectrometry

Retrieved on: 
星期二, 十一月 21, 2023
Hardware, Manufacturing, Other Manufacturing, Other Technology, Technology, Silicon carbide, Silicon nitride, IP, Spectroscopy, Risk, Corporation, Silicon, Fracture, Heat, Light, Kyocera, FTIR, Failure, Fig, Temperature, Ceramic

Kyocera Corporation, the world leader in Fine Ceramic technology, today introduced a Silicon Nitride (SN) light source for high-performance Fourier Transform Infrared (FTIR) spectrometers, developed using its SN heater and glow plug IP portfolio.

Key Points: 
  • Kyocera Corporation, the world leader in Fine Ceramic technology, today introduced a Silicon Nitride (SN) light source for high-performance Fourier Transform Infrared (FTIR) spectrometers, developed using its SN heater and glow plug IP portfolio.
  • View the full release here: https://www.businesswire.com/news/home/20231114555196/en/
    Kyocera develops silicon nitride light source for high-performance FTIR spectrometry (Photo: Business Wire)
    Kyocera’s SN heaters have been regarded as the most robust and fastest-ramping heaters in the world, durable enough to serve as glow plugs for diesel engines and igniters for industrial boilers, residential gas furnaces and Solid Oxide Fuel Cells (SOFCs).
  • Applied to spectrometry, Kyocera’s SN technology offers a light source with exceptional emissivity, which enables more accurate material identification.
  • Silicon nitride is well known as a robust material, with a long history of success in igniter and glow-plug applications.